ArticleFrontiers in immunology2026
Efficacy and safety of efgartigimod as an add-on therapy in patients with NMOSD and MOGAD at the acute attack phase.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein-associated disease (MOGAD) are autoimmune antibody-mediated diseases. Efgartigimod is a neonatal Fc receptor-targeting therapeutic that causes a reduction in the antibody titers. The efficacy and the safety of efgartigimod as an add-on therapy with intravenous methylprednisolone (IVMP) in patients with NMOSD and MOGAD were assessed in this study. Methods: In total, 27 adult patients diagnosed with NMOSD or MOGAD were enrolled, with 13 patients treated with IVMP plus efgartigimod and 14 comparable controls treated with IVMP alone. Efgartigimod was administered intravenously at 10 mg/kg at four doses or 20 mg/kg at two doses. The Expanded Disability Status Scale (EDSS) scores, the serum immunoglobulin G (IgG) levels, and the pathogenic antibody titers were evaluated before and after therapy. Results: Compared with IVMP alone, the efgartigimod group achieved better outcome with EDSS reduction of 1.3 ± 0.6 ( Conclusions: In this preliminary study, efgartigimod add-on therapy showed better trends than IVMP alone in accelerating short-term recovery in patients with NMOSD and MOGAD at the acute phase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.